An open-label evaluation of the safety and efficacy of a combination of niacin ER [extended-release] and simvastatin in patients with dyslipidaemia (OCEANS)

Trial Profile

An open-label evaluation of the safety and efficacy of a combination of niacin ER [extended-release] and simvastatin in patients with dyslipidaemia (OCEANS)

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jan 2008

At a glance

  • Drugs Niacin/simvastatin (Primary)
  • Indications Lipid metabolism disorders
  • Focus Adverse reactions; Registrational
  • Acronyms OCEANS
  • Most Recent Events

    • 08 Aug 2006 Status change
    • 10 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top